Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2

Leukemia and Lymphoma

Volumn 21, Issue 3-4, 1996, Pages 325-330

  Borrione, Paolo ^a   Montacchini, Laura ^a   Beggiato, Eloise ^a   Pileri, Alessandro ^a   Bianchi, Alberto ^a   Massaia, Massimo ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Advanced cancer; Anti CD3; IL 2; Immunotherapy; Lymphoma; Melanoma; Myeloma; OKT3

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DEXCHLORPHENIRAMINE; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY CD3; OKT 3; PARACETAMOL; PETHIDINE; PHYTOHEMAGGLUTININ; RANITIDINE; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CASE REPORT; CHILL; CLINICAL TRIAL; FEMALE; HEADACHE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MELANOMA; MULTIPLE MYELOMA; NATURAL KILLER CELL; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VOMITING;

EID: 0029924276     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199209067615     Document Type: Article

References (12)

1. Ioannides, C. G. and Whiteside, T. L. (1993) T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol., 66, 91-106.
2. Oliver, R. T. and Nouri, A. M. (1992) T cell immune response to cancer in humans and its relevance for immunodiagnosis and therapy. Cancer Surv., 13, 173-204.
3. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Lienhan, W. M., Robertson, C. M., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G. and White, D. E. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med., 316, 889-897.
4. Foa, R. (1993) Does interleukin-2 have a role in the management of acute leukemia? J. Clin. Oncol., 11, 1817-1825.
5. Rosenberg, S. A., Speiss, P. and Lafreiniere, R. (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 233, 1318-1321.
6. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Tapalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P. and White, D. E. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med., 319, 1676-1680.
7. Spits, H., Yasel, H., Leewenberg, J. and DeVrye, S. J. (1985) Antigen-specific cytotoxic T cell and antigen-specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur. J. Immunol., 15, 88-92.
8. Ting, C. C., Hargrove, E. M. and Yun, Y. S. (1988) Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. J. Immunol., 141, 741-748.
9. Scott, C. F., Lambert, J. M., Bolender, S. and Blatter, W. A. (1988) Resting human peripheral blood lymphocytes can be activated to cytolytic function by antibodies to CD3 in the absence of exogenous interleukin-2. Cell. Immunol., 114, 370-384.
10. Massaro, A. F., Schoof, D. D., Rubinstein, A., Zuber, M., Leonard-Vidal, F. J. and Eberlein, T. J. (1990) Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes. Cancer Res., 50, 2587-2592.
11. Grassland, K. D., Lee, V. K., Chen, W., Riddell, S. R., Greenberg, P. D. and Cheever, M. A. (1991) T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J. Immunol., 146, 4414-4420.
12. Anderson, P. M., Ochoa, A. C., Ramsay, N. K. C., Hasz, D. and Weisdorf, D. (1992) Anti-CD3 + Interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity. Blood, 80, 1846-1853.